Literature DB >> 22192876

Effects of anti-rVEGF on the expression of VEGF receptor-2 and P2X(2/3) receptors of the spinal dorsal horn in neuropathic pain rats.

Xin Li1, Guilin Li, Hong Xu, Xiaoli Tang, Yun Gao, Changshui Xu, Shuangmei Liu, Jinyan Xie, Guihua Tu, Haiying Peng, Shuyi Qiu, Shangdong Liang.   

Abstract

Neuropathic pain is caused by the peripheral or central nervous system structure damage or dysfunction. VEGF is involved in nociception and inflammation. VEGF may target VEGF receptor-2 (VEGFR-2) on the surface of neurons. P2X(2/3) receptors play a crucial role in facilitating pain transmission at the spinal sites. Chronic constriction injury (CCI) rats were used as neuropathic pain model. Sprague-Dawley male rats were randomly divided into sham group, anti-recombinant VEGF antibody group with phosphate-buffer saline (anti-rVEGF+PBS group), CCI rats treated with phosphate-buffer saline group (CCI+PBS group) and CCI rats treated with anti-recombinant VEGF antibody group (CCI+anti-rVEGF group). The expressions of VEGFR-2, P2X(2) and P2X(3) protein in spinal dorsal horn (SDH) were detected by immunohistochemistry, double-label immunofluorescence and western blotting. The protein levels of VEGFR-2, P2X(2) and P2X(3) in L4/5 SDH of CCI+PBS group were higher than those in sham group. VEGFR-2 and P2X(2) or P2X(3) receptors were co-expressed in the cytoplasm and surface membranes of SDH. Anti-rVEGF treatment in CCI rats reduced the expression of VEGFR-2 and P2X(2/3) receptors in L4/5 SDH compared with those in CCI+PBS group. Therefore, VEGF may activate VEGFR-2 to participate the process of neuropathic pain. Anti-rVEGF treatment in CCI rats reduced the expression of VEGFR-2 and inhibited the transmission of neuropathic pain in L4/5 SDH via decreasing the expression of P2X(2/3). There is a cross-potentiation between VEGFR-2 and P2X(2/3) receptors in neuropathic pain state.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22192876     DOI: 10.1016/j.brainresbull.2011.12.002

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  4 in total

1.  Nanoparticle-Encapsulated Curcumin Inhibits Diabetic Neuropathic Pain Involving the P2Y12 Receptor in the Dorsal Root Ganglia.

Authors:  Tianyu Jia; Jingan Rao; Lifang Zou; Shanhong Zhao; Zhihua Yi; Bing Wu; Lin Li; Huilong Yuan; Liran Shi; Chunping Zhang; Yun Gao; Shuangmei Liu; Hong Xu; Hui Liu; Shangdong Liang; Guilin Li
Journal:  Front Neurosci       Date:  2018-01-25       Impact factor: 4.677

2.  Bevacizumab for Treatment-Refractory Pain Control in Neurofibromatosis Patients.

Authors:  Xu W Linda; Lawrence D Recht
Journal:  Cureus       Date:  2016-12-18

3.  Central VEGF-A pathway plays a key role in the development of trigeminal neuropathic pain in rats.

Authors:  Geun W Lee; Jo Y Son; Ah R Lee; Jin S Ju; Yong C Bae; Dong K Ahn
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

4.  Delayed Imatinib Treatment for Acute Spinal Cord Injury: Functional Recovery and Serum Biomarkers.

Authors:  Jacob Kjell; Anja Finn; Jingxia Hao; Katrin Wellfelt; Anna Josephson; Camilla I Svensson; Zsuzsanna Wiesenfeld-Hallin; Ulf Eriksson; Mathew Abrams; Lars Olson
Journal:  J Neurotrauma       Date:  2015-06-11       Impact factor: 5.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.